Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.
Prevention gets tech budget it deserves as a $499, hour-long body scan backed by Zuckerberg and Sharapova lands in SoHo.
Leisure exercise lowers dementia risk, while physically demanding jobs may raise it – twist that reshapes how we think about ...
NeuLogiq platform earned high marks from ALS and FTD patients using it at home, addressing a gap left by motor-only rating ...
Researchers say disrupted sleep may be one of the earliest signs of Alzheimer’s, arriving years before memory loss and ...
Genetic LifeSpan launch MyHeartCode, betting that epigenetic data can tell people more about their heart than cholesterol ...
While Spain celebrates football glory, Madrid scores for a longer future – José Cordeiro dives into the International ...
South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward ...
Six proteomic clocks detect a younger biological age signal in an IPF trial – but separating geroprotection from treatment ...
PRGS&Tech is South Korea’s only team left in XPRIZE Healthspan’s $110 million race to prove a drug can help everyone age more ...
Licensing deal brings Amprion’s misfolded-protein test closer to European trial sites, aiming to speed up neurodegenerative ...
Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results